mTOR-Mediated Desaturation of Fatty Acids in Hepatic Insulin Resistance.

mTOR 介导的肝胰岛素抵抗中脂肪酸去饱和。

• 批准号: 10554280
• 负责人: Adam Salmon
• 金额: --
• 依托单位: SOUTH TEXAS VETERANS HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10554280
• 关键词: Acyl Coenzyme A; Address; Affect; Animals; Automobile Driving; Biogenesis; Catabolism; Cell Culture Techniques; Cells; Coenzyme A; Complex; Data; Defect; Development; Diet; Diet Modification; Dietary Fats; Dietary Fatty Acid; Enzymes; Etiology; FRAP1 gene; Fatty Acids; Fatty acid glycerol esters; Functional disorder; Genetic; Goals; Health; Healthcare; Hepatic; Hepatocyte; Homeostasis; Impairment; Insulin; Insulin Resistance; Knockout Mice; Link; Liver; Liver Mitochondria; Mediating; Mediator; Metabolic; Metabolic Diseases; Metabolic dysfunction; Metabolic stress; Metabolism; Mitochondria; Morphology; Mus; Non-Insulin-Dependent Diabetes Mellitus; Nutrient; Nutrient availability; Nutritional; Outcome; Oxidoreductase; Pathology; Pathway interactions; Patients; Pharmacologic Substance; Play; Prevalence; Prevention; Primary carcinoma of the liver cells; Process; Regulation; Research; Risk; Role; Saturated Fatty Acids; Services; Signal Transduction; Source; Testing; Tissues; Unsaturated Fats; Unsaturated Fatty Acids; Veterans; Veterans Health Administration; Work; cost; dietary; fatty acid metabolism; fatty acid oxidation; flexibility; functional outcomes; genetic manipulation; glucose production; improved; insulin sensitivity; insulin signaling; lipid biosynthesis; lipid metabolism; member; mortality; mouse model; mutant mouse model; new therapeutic target; non-alcoholic fatty liver disease; novel; oxidation; pi bond; preference; prevent; response; saturated fat

Discharged members of the US Armed Services are at an increased risk of metabolic disease which is exemplified by the prevalence of type 2 diabetes mellitus (T2DM) affecting an estimated 1/3 of all VHA patients. A key defect in the etiology of T2DM is the inability of insulin to suppress hepatic glucose production, or hepatic insulin resistance. Alterations in hepatic lipid metabolism precede hepatic insulin resistance and are regulated largely by mitochondrial fatty acid oxidation (β-oxidation) and, in particular, the ability to maintain effective metabolic flexibility under different dietary states. Previous work has implicated mechanistic target of rapamycin (mTOR) as a mediator of this process through the regulation of β-oxidation. However, our preliminary work found an interesting dichotomy; inhibition of mTOR promotes β-oxidation of fatty acids when there is a prevalence of saturated fatty acids substrates available but in contrast impairs β-oxidation when unsaturated fatty acids are the primary dietary lipid sources. That is, unsaturated fatty acid catabolism by β- oxidation is not complete in the context of low mTOR singaling. β-oxidation of unsaturated fatty acids requires accessory enzymes to desaturate for use as mitochondrial substrates. Because the development of insulin resistance is linked to dysregulation in metabolic flexibility, we propose that mTOR-mediated regulation of this process is a key to maintaining hepatic insulin sensitivity and preventing metabolic disease. The long-term goal of this proposal is define a relationship that could be central to the development of hepatic insulin resistance. This metabolic dysfunction is highly prevalent among Veterans and is a significant long-term healthcare issue due to increased risk of developing additional pathologies associated with this condition, including non-alcoholic fatty liver disease and hepatocellular carcinoma. Treatment and prevention options will significantly reduce the health burden of Veteran patients as well as Veterans Health Administration costs associated with treatment. Our overall hypothesis is that mTOR regulates the response to dietary fatty acids through its regulation of β-oxidation accessory enzymes and that dysfunction in this pathway leads to hepatic insulin resistance. Our rationale for this study is that understanding how this pathway regulates nutrient usage under metabolic stress will serve as a means to define new therapeutic targets to be utilized for treatment and prevention of metabolic disease in Veterans. We test this hypothesis using both pharmaceutical and genetic manipulation of mTOR signaling and the rate limiting β-oxidation accessory enzyme 2,4 Dieonyl-CoA reductase (DECR1) in primary hepatocytes and mouse models in experimental aims that link this pathway with mitochondrial energetic function and metabolism. In aim 1, we test whether mTOR signaling has direct impact on the activity of DECR1 with a functional outcome on fat oxidation. In aim 2, we then test whether β-oxidation accessory enzymes in mice play a significant role in the development of hepatic insulin signaling under metabolic stress using a novel DECR1 knockout mouse model. In particular, we test the metabolic and mitochondrial response to metabolic stress from changing dietary sources of fat. In aim 3, we address remodeling of the hepatic mitochondria as a homeostatic mechanism to maintain metabolic flexibility and the potential role of β-oxidation accessory enzymes in this process. Hepatic insulin resistance is promoted by several factors including diet, genetics and liver pathology. By clarifying a central pathway in the process through mTOR and β-oxidation accessory enzymes, our approach will lead to breakthrough discoveries that will significantly enhance health research to help our Veterans.

退役的美国军人患代谢性疾病的风险增加，这是